TLR3 binding agents
US9944712B2 · kind B2 · utility
0Cited by
24References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 30, 2013 |
| Grant date | Apr 17, 2018 |
| Priority date | — |
| Expiry date | May 26, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.